FiercePharma
@FiercePharma
Pharma’s go-to destination for news & trends shaping approved drugs. Delivering news, revealing insights straight to your inbox.
466 Following 100.8K Followers
AstraZeneca snagged a recommendation from the CHMP, setting dual-binding nanobody C5 inhibitor Klygefa up for a formal approval in Europe.
In an interview with Fierce, Novo CEO Mike Doustdar opened up about the company's recent rebrand and it's aim to look toward the future while still honoring its Danish heritage
BMS, Ono take Amgen to task as FDA's Opdivo biosimilar decision looms
After a run of dealmaking, Gilead CEO Daniel O'Day told Fierce that any future M&A activity will only be done to complement the existing strategy. @GileadSciences
Sanofi strikes Cheplapharm deal to divest 20 older medicines as CEO pushes for innovation
AbbVie chips in for neurology advocacy through PGA Tour birdie campaign
In his first interview since taking over the FDA's oncology arm, Angelo de Claro talks efficiency, innovation, and continuing the OCE's legacy
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative Qulipta.
In a stabilizing move, the Department of Health and Human Services has tapped Michael Davis, M.D., Ph.D., and Karim Mikhail—who’ve been serving as acting directors of the Centers for Drugs Evaluation and Research (CDER) and the Centers for Biologics Evaluation and Research (CBER), respectively—to occupy their posts on a permanent basis.
Show more
In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival win in first-line small cell lung cancer.
Daiichi Sankyo subsidiary American Regent is launching a recall of three lots of generic epinephrine as it becomes one of the latest manufacturers to face headaches over particulate contamination in its drug products.
Show more
Martina Flammer helped advance brensocatib from development through FDA approval as the first DPP1 inhibitor for bronchiectasis. She is a 2026 Fierce 50 Breakthrough honoree. 🔗 @Insmed #Fierce50#
Show more
As part of the MFN drug pricing deal the Trump administration signed with obesity giants Eli Lilly and Novo Nordisk, Medicare recently launched a “bridge” model, offering weight loss drugs to eligible seniors at $50 per month. Now, we know the initial uptake from the program.
Show more
Congrats to Eric Topol, one of this year’s Fierce 50 Leadership honorees, recognized for decades of work advancing digital medicine and for helping define both the promise and limits of AI in healthcare.
Show more
Thanks for the leadership recognition @FiercePharma @FierceBiotech
The 2026 Fierce 50 is live.
This year’s honorees include leaders, scientists, companies and organizations changing how drugs are developed, healthcare is delivered and patients navigate the system.
Meet the Fierce 50:
Show more
An inexperienced RevMed is now responsible for launching the most hotly anticipated cancer drug in years.
Jazz's HER2 bispecific Ziihera gains FDA approval to change practice in stomach cancer
